Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scilex Holding CoSCLX +2.15%55 Forward PE Ratio is 1.90 as of Jul. 21, 2026. GuruFocus rates SCLX with a GF Score™ of 55/100 and a GF Value™ of $5.90 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 409 Drug Manufacturers companies, Scilex Holding Co ranks better than 98.78% on this metric.
Scilex Holding Co (NAS:SCLX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Scilex Holding Co Forward PE Ratio Related Terms
Scilex Holding Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co Forward PE Ratio Chart
Scilex Holding Co Annual Data
Trend
2025-12
Forward PE Ratio
4.53
Scilex Holding Co Quarterly Data
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
0.81
2.77
9.39
4.53
2.66
SCLX vs MIRA, NSRX, MDCX: Forward PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Scilex Holding Co (SCLX) has a Forward PE Ratio of 1.90 as of Jul. 21, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Scilex Holding Co and its competitors. According to the industry distribution chart, Scilex Holding Co ranks #5 out of 409 companies in the Drug Manufacturers industry, placing it in the top 1.2%.
Is Scilex Holding Co's Forward PE Ratio too high?
Scilex Holding Co's current Forward PE Ratio is 1.90. The Drug Manufacturers industry median Forward PE Ratio is 17.21. Scilex Holding Co's value of 1.90 is 89% below this industry median. Based on the distribution chart, Scilex Holding Co ranks #5 out of 409 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scilex Holding Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Forward PE Ratio compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #5 out of 409 companies for Forward PE Ratio. This places Scilex Holding Co in the top 1% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.21. Scilex Holding Co's value of 1.90 is 89% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.21, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scilex Holding Co's current Forward PE Ratio of 1.90 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Forward PE Ratio is 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.90, compared to a current price of $7.95 — trading 34.7% above its estimated fair value. The current Forward PE Ratio is 1.90 and 89% below the Drug Manufacturers industry median of 17.21. Scilex Holding Co's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Forward PE Ratio is 1.90 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of $7.95 is trading 34.7% above its estimated GF Value™ of $5.90.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for SCLX:
Forward PE Ratio: 1.90
GF Value™: $5.90 vs. price of $7.95 (34.7% above fair value)
Industry Position: 89% below the Drug Manufacturers median (#5 of 409)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
55GF Score
Get the complete analysis for SCLX
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
